Announcements Trials
Browse Landscape

Status

Recruiting 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 54Neoplasms 47Colorectal Neoplasms 31Prostatic Neoplasms 27Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 21Leukemia, Myeloid, Acute 19Recurrence 12Stomach Neoplasms 11Multiple Myeloma 11Melanoma 11Head and Neck Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Ovarian Neoplasms 9Uterine Cervical Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Pancreatic Neoplasms 8Neoplasm Metastasis 8Myelodysplastic Syndromes 8Lymphoma, Non-Hodgkin 8Lymphoma 8Glioma 8Brain Neoplasms 8Motor Activity 7Esophageal Neoplasms 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Leukemia 6Hodgkin Disease 6Colonic Neoplasms 6

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Hemorrhage × 30 days × Clear all
NCT07527832 2026-06-03

An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.

Pfizer

Completed
1,000 enrolled
Gastrointestinal

Hemorrhage, Colorectal Neoplasms

NCT06170619 2026-06-01

OCCLUDE

Boston Scientific Corporation

Completed
125 enrolled

Hemorrhage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡